Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kyle Eberlin

Plastic and Reconstructive Surgery Boston, MA Medical Doctor

NPI 1386844165 CMS profile 290116

55 Fruit St # St-435, Massachusetts General Hospital, Boston, MA 02114

Open in the dashboard

General payments

$445,250

425 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$26,500 paid to institutions, not to them · program year 2022

Through program year 2025, Kyle Eberlin of Boston, MA is reported in the CMS Open Payments database as having received $445,250 across 425 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,414 38
2024 General $66,399 67
2023 General $114,671 85
2022 General $54,937 54
2021 General $44,363 50
2020 General $21,774 31
2019 General $107,691 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Eberlin
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Kyle Eberlin were reported at $35,414. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Kyle Eberlin Plastic and Reconstructive Surgery median Middle half National median
2019 $107,691 $335 $121–$1,264 $163
2020 $21,774 $162 $57–$417 $114
2021 $44,363 $245 $89–$735 $132
2022 $54,937 $325 $120–$932 $149
2023 $114,671 $343 $129–$999 $160
2024 $66,399 $390 $141–$1,085 $164
2025 $35,414 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AxoGen $267,587 216 payments
  2. Integra LifeSciences Corporation $109,541 119 payments
  3. Checkpoint Surgical, Inc $29,385 25 payments
  4. Biocircuit Technologies Inc $15,806 12 payments
  5. Medical Device Business Services, Inc. $13,887 15 payments
  6. Bioventus LLC $4,179 4 payments
  7. Tulavi Therapeutics, Inc. $1,697 4 payments
  8. TriMed, Inc. $682 7 payments
  9. Synthes GmbH $500 1 payment
  10. Bioness Inc $408 2 payments
  11. Other $1,578 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $241,084 77 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $80,238 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,556 18 payments
  4. Travel and Lodging $40,884 88 payments
  5. Food and Beverage $27,756 222 payments
  6. Honoraria $1,500 1 payment
  7. Entertainment $232 1 payment
Products named General payments · program years 2019–2025
  1. AXOGUARD NERVE PROTECTOR $198,289 126 payments
  2. AxoGuard Nerve Connector $198,289 126 payments
  3. Avance Nerve Graft $176,122 134 payments
  4. Integra Recon-Skin And Wound $64,134 60 payments
  5. Integra Recon-Skin And Wound $63,855 59 payments
  6. Checkpoint Stimulators $29,385 25 payments
  7. TENOGLIDE TENDON PROTECTOR SHEET $23,384 9 payments
  8. AXOGUARD NERVE CAP $16,981 19 payments
  9. Axoguard HA+ Nerve Protector $16,981 19 payments
  10. IDRT $14,934 28 payments
  11. Other $183,408 388 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$164,612

Of which drugs: $4,950

Medicare patients

284

Average age 68

Services billed

934

145 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 57%
Depression 31%
Diabetes 25%
Ischemic heart disease 24%
Chronic kidney disease 22%
Osteoporosis 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 31 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

425 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record